|
Congressional:
Appropriation Bill Package Signed into Law, Ending Brief Partial Government Shutdown
On Tuesday, the House passed in a 217-214 vote, the Senate Amendments to H.R. 7148 (Consolidated Appropriations Act, 2026), which includes a two-week extension of funding for the Department of Homeland Security and related agencies through February 13. President Trump signed the bill into law the same day, ending a four-day partial government shutdown. The package includes FY2026 funding for the Department of Health and Human Services through September 30, as well as an additional health care package. The Senate passed the measure last week by a vote of 71-29. Now, all attention turns to the new February 13 deadline and a major question about whether policy differences between Republicans and Democrats regarding immigration reform and the Immigration and Customs Enforcement (ICE) agency's enforcement strategies. Democratic Leader Chuck Schumer (D-NY) outlined reforms Democrats would like to see, while Senator Katie Britt (R-AL), a key negotiator, has said many items are nonstarters.
Senate HELP Committee Holds Hearing on Modernizing the NIH
On Tuesday, the Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing on modernizing the National Institutes of Health (NIH) with NIH Director Jayanta Bhattacharya. During the hearing, Senators from both parties asked Bhattacharya about the millions of dollars in grants the NIH canceled or suspended last year, as well as the Trump administration’s shifts in vaccine policy. Senator Bill Cassidy (R-LA), the chair of the Committee, along with several Democratic senators, criticized the agency’s approach to vaccinations and mixed messages coming from Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. Bhattacharya repeatedly told the committee that he did not believe the measles, mumps, and rubella (MMR) vaccine was linked to autism. Read Mehlman’s hearing summary here.
House E&C Committee Holds Hearing on Medicare and Medicaid Fraud
On Tuesday, the House Energy and Commerce Oversight and Investigations Subcommittee held a hearing to examine fraud in Medicare and Medicaid. Full Committee Chair Brett Guthrie (R-KY) stated that the hearing was necessary because of widespread fraud in the two federal health programs. He pointed to Operation Gold Rush, a Department of Justice investigation that led to the charging of 324 defendants last year for stealing personal data from Medicare beneficiaries. Democrats criticized the Trump administration for using fraud allegations to justify punitive actions against Democratic-led states, warning that this undermines real anti-fraud efforts and can harm communities. Both parties agreed that fraud, waste, and abuse in Medicare and Medicaid are serious problems, and that improved oversight, data infrastructure, and collaboration are needed to address them. Witnesses included: Integrity Advantage Vice President Jessica Gay; National Association of State Medicaid Fraud Control Units President Kaye Lynn Wootton; Coastal Carolina Health Care CEO Stephen Nuckolls; and Government Contracts Advisory Council Distinguished Professorial Lecturer in Government Contracts Law member Jessica Tillipman. Read Mehlman’s hearing summary here.
Senate Democrats Outline New Agenda for Lower Drug Prices
On Wednesday, Senate Finance Committee Ranking Member Ron Wyden (D-OR), along with Senators Catherine Cortez Masto (D-NV), Peter Welch (D-VT), and Ruben Gallego (D-AZ), announced a new effort to lower the cost of prescription drugs in a Dear Colleague letter. The letter lays out three goals: lower the prices that drug manufacturers charge by strengthening and expanding Medicare’s ability to negotiate and rein in policies that drive up list prices; reduce out-of-pocket costs and limit markups and middleman profits in the drug supply chain; and preserve and strengthen American biomedical innovation by maintaining incentives for research and development while making medicines more affordable. Read the press release here and the letter here.
Senator Sanders Releases New Report on Trump Administration and NIH Research
On Tuesday, Senator Bernie Sanders (I-VT), Ranking Member of the Senate Committee on Health, Education, Labor, and Pensions (HELP), released a new report titled “Putting Cures Out of Reach: Trump's National Institutes of Health.” The report analyzes NIH data and draws from interviews with federal scientists, researchers, and workers. It found that NIH has terminated or frozen at least $561 million in research on four of the leading causes of death. The report also found that every drug invented with help from NIH scientists was sold at a lower price in other countries than in the United States. Read the press release and report here.
Notable Bills:
Representatives Carter, Peters, Langworthy, Levin, Carey Reintroduce Bill Encouraging Drug Development to Combat Antimicrobial Resistance
On Thursday, Representatives Buddy Carter (R-GA), Scott Peters (D-CA), Nick Langworthy (R-NY), Mike Levin (D-CA), and Mike Carey (R-OH) introduced the bipartisan Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act to encourage innovative drug development targeting the most threatening infections, improve the appropriate use of antibiotics and antifungals, and ensure domestic availability of critical antimicrobials when needed. Read the press release here and the bill here.
Senators Cotton, Klobuchar Introduce Bill to Establish Federal Biotech Security Framework
On Wednesday, Senators Tom Cotton (R-AR) and Senator Amy Klobuchar (D-MN) introduced legislation to establish a federal biosecurity framework. The Biosecurity Modernization and Innovation Act would require gene synthesis providers to screen their orders and customers for bad actors or dangerous pathogens and would ensure that the U.S. government adopts a flexible, agile approach to biosecurity to maintain American leadership. Read the press release here and the bill here.
Representative Schakowsky, Bipartisan Colleagues Reintroduce ALS Better Care Act to Expand Access to Specialized Care
On Tuesday, Representatives Jan Schakowsky (D-IL), Brian Fitzpatrick (R-PA), Jason Crow (D-CO), and Mike Quigley (D-IL) reintroduced the ALS Better Care Act, bipartisan legislation to expand access to specialized, multidisciplinary care for people living with amyotrophic lateral sclerosis (ALS) at no cost by creating a supplemental, facility-based payment in Medicare for ALS-related services. U.S. Senators Lisa Murkowski (R-AK) and Chris Coons (D-DE) introduced companion legislation in the Senate. Read the press release here and the bill here.
Executive Branch:
Trump Unveils TrumpRx Direct-To-Consumer Drug Website
On Thursday, President Trump launched his direct-to-consumer prescription drug access website, TrumpRx. The website allows patients to search for a specific medicine and then directs them to drug companies’ platforms to buy the product at a reduced rate. According to a White House fact sheet, as of Thursday, 40 branded medicines are available for purchase through the TrumpRx website. The 40 medicines are from the first five drugmakers to sign most-favored-nation agreements with the Trump administration — AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. Trump stated that more drugs would soon be added. Read the White House fact sheet here and see the website here.
FTC Secures Settlement with Express Scripts to Lower Drug Costs
On Wednesday, the Federal Trade Commission (FTC) announced it had secured a settlement with one of the nation’s largest pharmacy benefit managers (PBMs), Express Scripts, Inc., and its affiliated entities. The settlement requires Express Scripts to adopt changes to its business practices that increase transparency and are expected to reduce patients’ out-of-pocket drug costs by up to $7 billion over 10 years. The FTC’s settlement resolves the Commission’s 2024 lawsuit against Express Scripts, which alleges that Express Scripts artificially inflated the list price of insulin drugs by using anticompetitive rebating practices. In the agreement, Express Scripts committed to stop favoring drugs with high wholesale acquisition costs on its standard formularies when an identical, lower-priced version is available. The PBM will also provide clients with a standard offering that ensures patients’ out-of-pocket expenses will be based on a medicine’s net cost, instead of its list price. Read the press release here.
HHS Secretary Kennedy Announces $100 Million Investment in “Great American Recovery”
On Monday, Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. announced a $100 million investment to solve long-standing homelessness issues, fight opioid addiction, and improve public safety by expanding treatment that emphasizes recovery and self-sufficiency. The Safety Through Recovery, Engagement, and Evidence-based Treatment and Supports (STREETS) Initiative will fund targeted outreach, psychiatric care, medical stabilization and crisis intervention, while connecting Americans experiencing homelessness and addiction to stable housing with a clear focus on long-term recovery and independence. Read the press release here.
Medicaid Technology Companies Pledge $600M in Savings to Support Community Engagement and Related State Medicaid System Improvements
Late last week, the Centers for Medicare & Medicaid Services (CMS) announced that 10 health technology companies that have existing Medicaid eligibility and enrollment contracts with states have voluntarily pledged to help states successfully prepare for and implement Medicaid community engagement requirements enacted under the One Big Beautiful Bill Act (Public Law 119-21). Companies that currently support state Medicaid systems have informed CMS that they intend to offer states more than $600 million in no-cost and significantly discounted technology products and services to support community engagement implementation and accelerate the broader modernization of Medicaid systems. Read the press release here and the fact sheet here.
|